Bristol-Myers Squibb Co (BMY) and Pfizer (PFE) announced that FDA has extended action date for Eliquis by three months.
FDA extended action date for the New Drug Application or NDA for Eliquis for prevention of stroke and systemic embolism in patients with atrial fibrillation. The new Prescription Drug User Fee Act goal date is June 28.
Subsequent to NDA filing, the companies submitted additional information about the Eliquis clinical program to FDA, which constitutes a major amendment to application and will require additional time for review.
The companies stated that they will continue to work closely with the agency to support the continued review of the NDA for Eliquis.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.